AstraZeneca PLC (AZN)vsExelixis Inc (EXEL)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
EXEL
Exelixis Inc
$56.21
+0.16%
HEALTHCARE · Cap: $14.62B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2419% more annual revenue ($61.37B vs $2.44B). EXEL leads profitability with a 35.3% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.28. EXEL earns a higher WallStSmart Score of 70/100 (B-).
AZN
Buy60
out of 100
Grade: C+
EXEL
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+64.9%
Fair Value
$164.33
Current Price
$56.21
$108.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 47 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 39.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 26.2% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.3% and operating margin at 39.5%. Revenue growth of 10.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Key Dynamics to Monitor
EXEL carries more volatility with a beta of 0.42 — expect wider price swings.
EXEL is growing revenue faster at 10.6% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EXEL scores higher overall (70/100 vs 60/100), backed by strong 35.3% margins and 10.6% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?